Special Issue "Therapeutic Tumor Vaccine"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 30 January 2023 | Viewed by 135

Special Issue Editor

Dr. Isabella Lurje
E-Mail Website
Guest Editor
Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Interests: immunotherapy; cancer vaccination; primary liver cancer; liver immunology

Special Issue Information

Dear Colleagues,

Tumor vaccination combines the success story of tumor immunotherapy with the advances in precision and personalized medicine. The research field of tumor vaccination has rapidly expanded over the last decade, encompassing in vitro approaches such as T-cell transfer therapy, antigen-presenting cell-directed approaches, in situ vaccination, and the use of oncolytic viruses, all with the aim of eliciting or restoring an efficient antitumor response. However, so far, only a few therapeutic strategies have reached clinical implementation (and predominantly in hematological malignancies, not solid tumors), despite promising preclinical data and sophisticated immunological techniques. The most widely known prophylactic vaccine against an oncological disease, the HPV vaccine, has already witnessed encouraging success in clinical translation.

The main focus of this Special Issue is to critically assess current strategies in the field of vaccines, both against established tumors and in prophylactic intent, to shed light on new emerging concepts as well as to illustrate the effect of cancer vaccines on tumors, the tumor microenvironment and on systemic immunology. All strategical aspects, including the identification of tumor-associated antigenes, myeloid and lymphoid cell targeting and function, as well as delivery platforms for tumor vaccines, are of interest for this Special Issue. We also invite papers that describe the advantages and disadvantages of clinical translation of tumor vaccines.

In summary, submissions, including original research, reviews or methods papers on all aspects of tumor vaccination are very welcome. We sincerely hope that this Special Issue may serve as a platform for exchanging important developments in tumor vaccinations for human tumors and will contribute to the understanding and therapy of oncological diseases.

Dr. Isabella Lurje
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • tumor vaccination
  • CAR T-cell therapy
  • antigen-presenting cells
  • oncolytic virus
  • cancer immunotherapy

Published Papers

This special issue is now open for submission.
Back to TopTop